NCT00938041View on ClinicalTrials.gov

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 1998

Primary Completion Date

May 31, 2003

Study Completion Date

June 30, 2013

Conditions
Lymphoma, Non-Hodgkin
Interventions
BIOLOGICAL

Tositumomab and Iodine I 131 Tositumomab

Tositumomab and Iodine I 131 Tositumomab

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY